Literature DB >> 16793311

Enhanced susceptibility of multidrug resistant strains of Mycobacterium tuberculosis to granulysin peptides correlates with a reduced fitness phenotype.

Juan Carlos Toro1, Sven Hoffner, Charlotte Linde, Mats Andersson, Jan Andersson, Susanna Grundström.   

Abstract

Previously it was shown that the antimicrobial protein granulysin possesses potent membranolytic activity against Mycobacterium tuberculosis. Here we demonstrate that granF2 and G13, which are two short synthetic peptides derived from granulysin, inhibited the in vitro growth of clinical isolates of both multidrug resistant and drug susceptible strains of M. tuberculosis. Importantly, a particularly high activity against multidrug resistant M. tuberculosis correlated with a reduced growth rate compared to drug susceptible strains. A synergistic antibacterial effect of granF2 was further observed in combination with ethambutol, a compound with a documented effect on cell wall permeability. This finding suggests that granF2 and ethambutol exert their functions at different levels of the mycobacterial surface. Upon infection of macrophages in vitro, granF2 but not G13 efficiently reduced the intracellular growth of multidrug resistant M. tuberculosis in the presence of the pore-forming protein streptolysin O. The apoptotic function of granF2 apparently promoted destruction of host cells whereby the peptide gained access to and killed intracellular bacteria. Thus, a cost of resistance and a subsequent reduced fitness, measured as decreased growth among multidrug resistant strains of M. tuberculosis, could be associated with increased susceptibility to natural immune defense mechanisms, such as antimicrobial peptides of granulysin. However, a robust cell wall and the membrane of cells still provide physical shelter for the bacteria that may spare sensitive M. tuberculosis stains from being killed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793311     DOI: 10.1016/j.micinf.2006.02.030

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  8 in total

1.  Inhalation of recombinant adenovirus expressing granulysin protects mice infected with Mycobacterium tuberculosis.

Authors:  J Ma; J Lu; H Huang; X Teng; M Tian; Q Yu; X Yuan; Y Jing; C Shi; J Li; X Fan
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

2.  Strong Environment-Genotype Interactions Determine the Fitness Costs of Antibiotic Resistance In Vitro and in an Insect Model of Infection.

Authors:  C James Manktelow; Elitsa Penkova; Lucy Scott; Andrew C Matthews; Ben Raymond
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

3.  Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy.

Authors:  Diana Di Liberto; Simona Buccheri; Nadia Caccamo; Serena Meraviglia; Amelia Romano; Paola Di Carlo; Lucina Titone; Francesco Dieli; Alan M Krensky; Alfredo Salerno
Journal:  Tuberculosis (Edinb)       Date:  2007-03-26       Impact factor: 3.131

Review 4.  Biology and clinical relevance of granulysin.

Authors:  A M Krensky; C Clayberger
Journal:  Tissue Antigens       Date:  2009-03

5.  Anti-mycobacterial activity evaluation of designed peptides: cryptic and database filtering based approach.

Authors:  Sneha Raj; Umamageswaran Venugopal; Garima Pant; Mitra Kalyan; Jesu Arockiaraj; Manju Y Krishnan; Mukesh Pasupuleti
Journal:  Arch Microbiol       Date:  2021-07-09       Impact factor: 2.552

Review 6.  Nanobead-based interventions for the treatment and prevention of tuberculosis.

Authors:  Gareth Griffiths; Bo Nyström; Suraj B Sable; Gopal K Khuller
Journal:  Nat Rev Microbiol       Date:  2010-10-12       Impact factor: 60.633

7.  Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia.

Authors:  Demelash Assefa; Berhanu Seyoum; Lemessa Oljira
Journal:  Infect Drug Resist       Date:  2017-07-11       Impact factor: 4.003

8.  Enhanced tuberculosis clearance through the combination treatment with recombinant adenovirus-mediated granulysin delivery.

Authors:  Ling Hao; Jilei Ma; Chunwei Shi; Xiaosong Lin; Yandi Zhang; Banga Ndzouboukou Jo-Lewis; Qing Lei; Nadeem Ullah; Zhongjie Yao; Xionglin Fan
Journal:  Theranostics       Date:  2020-08-08       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.